| # | Title | Journal | Year | Citations |
|---|
| 1 | Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial | Lancet, The | 2021 | 689 |
| 2 | Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2017 | 398 |
| 3 | Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial | Lancet Respiratory Medicine,the | 2017 | 252 |
| 4 | Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301) | Lancet Oncology, The | 2012 | 213 |
| 5 | Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT) | Clinical Cancer Research | 2019 | 191 |
| 6 | Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer | Journal of Thoracic Oncology | 2012 | 166 |
| 7 | Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System | PLoS ONE | 2013 | 151 |
| 8 | Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04) | Cancer | 2018 | 147 |
| 9 | Biologic Correlation of 2-[18F]-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors | Journal of Clinical Oncology | 2010 | 143 |
| 10 | Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer | Supportive Care in Cancer | 2015 | 129 |
| 11 | Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports | Cancer Science | 2011 | 128 |
| 12 | Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study | Journal of Thoracic Oncology | 2013 | 127 |
| 13 | Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial | Lancet Oncology, The | 2020 | 124 |
| 14 | Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial | Lancet Oncology, The | 2016 | 122 |
| 15 | Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2020 | 117 |
| 16 | A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study) | Annals of Oncology | 2015 | 110 |
| 17 | Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study | Lancet Oncology, The | 2014 | 106 |
| 18 | Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non‐small‐cell lung cancer | Journal of Cachexia, Sarcopenia and Muscle | 2019 | 106 |
| 19 | Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan | International Journal of Clinical Oncology | 2015 | 102 |
| 20 | The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV | International Journal of Clinical Oncology | 2019 | 100 |
| 21 | A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia | Cancer | 2019 | 99 |
| 22 | Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer | Lung Cancer | 2014 | 98 |
| 23 | A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L | Annals of Oncology | 2015 | 90 |
| 24 | Imaging of gefitinib-related interstitial lung disease: Multi-institutional analysis by the West Japan Thoracic Oncology Group | Lung Cancer | 2006 | 88 |
| 25 | A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy | Lung Cancer | 2016 | 88 |
| 26 | Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure | Lung Cancer | 2011 | 80 |
| 27 | Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma | Lung Cancer | 2010 | 79 |
| 28 | Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure | Cancer Science | 2016 | 78 |
| 29 | Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4) | Cancer Chemotherapy and Pharmacology | 2012 | 77 |
| 30 | IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). | Journal of Clinical Oncology | 2021 | 77 |
| 31 | Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2015 | 75 |
| 32 | LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. | Journal of Clinical Oncology | 2012 | 74 |
| 33 | Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors | Japanese Journal of Clinical Oncology | 2010 | 70 |
| 34 | Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single‐institute study | Cancer | 2014 | 65 |
| 35 | Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer | Lung Cancer | 2010 | 64 |
| 36 | A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901) | Lung Cancer | 2014 | 62 |
| 37 | Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease | Cancer Chemotherapy and Pharmacology | 2015 | 62 |
| 38 | Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT) | Journal of Clinical Oncology | 2022 | 61 |
| 39 | LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. | Journal of Clinical Oncology | 2012 | 60 |
| 40 | Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study | Annals of Oncology | 2013 | 59 |
| 41 | Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer | ESMO Open | 2017 | 58 |
| 42 | Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer | Lung Cancer | 2010 | 52 |
| 43 | Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non–small-cell lung cancer | BMC Cancer | 2017 | 51 |
| 44 | Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study | Journal of Thoracic Oncology | 2022 | 51 |
| 45 | Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease | Cancer Science | 2019 | 49 |
| 46 | Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer | JAMA Oncology | 2020 | 48 |
| 47 | Correlation Between 18F-FDG Uptake on PET and Molecular Biology in Metastatic Pulmonary Tumors | Journal of Nuclear Medicine | 2011 | 46 |
| 48 | Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma | European Journal of Cancer | 2012 | 46 |
| 49 | Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation | BMC Cancer | 2013 | 46 |
| 50 | Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study | BMC Cancer | 2017 | 46 |
